Pridopidine in the pharmacological treatment of Huntington’s disease

Author： Michl Martin   Schnopfhagen Katharina   Bonelli Raphael M  

Publisher： Future Science

ISSN： 2041-6792

Source： Clinical Investigation, Vol.3, Iss.7, 2013-07, pp. : 691-699

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The pridopidine paradox in Huntington's disease

By  

MOVEMENT DISORDERS, Vol. 28, Iss. 10, 2013-09 ,pp. : 1321-1324

John Wiley & Sons Inc

Access to resources Recommend Favorite

Mechanisms of neuronal cell death in Huntington’s disease

By  

Cytogenetic and Genome Research, Vol. 100, Iss. 1-4, 2003-10 ,pp. : 287-295

Karger

Access to resources Recommend Favorite

A randomized, double‐blind, placebo‐controlled trial of pridopidine in Huntington's disease

By  

MOVEMENT DISORDERS, Vol. 28, Iss. 10, 2013-09 ,pp. : 1407-1415

John Wiley & Sons Inc

Access to resources Recommend Favorite

Normal and Pathological Aging of Attention in Presymptomatic Huntington’s, Huntington’s and Alzheimer’s Disease, and Nondemented Elderly Subjects

By  

Psychotherapy and Psychosomatics, Vol. 77, Iss. 3, 2008-02 ,pp. : 139-146

Karger

Access to resources Recommend Favorite

Human Fetal Striatal Transplantation in Huntington’s Disease: A Refinement of the Stereotactic Procedure

By  

Stereotactic and Functional Neurosurgery, Vol. 86, Iss. 5, 2008-09 ,pp. : 308-313

Karger

Access to resources Recommend Favorite